GTBP News and Press, GT Biopharma Inc. From 01/20/22

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference PR Newswire BRISBANE, Calif. , Jan. 20, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics base...

GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) PR Newswire BRISBANE, Calif. , Jan. 6, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative t...

Preclinical data on GT Biopharma's (NASDAQ:GTBP) GTB-5550 found that the candidate induces natural killer cell activation against a broad spectrum of tumors expressing B7-H3. Shares are up more than 12% in premarket trading. The company also found that a dual camelid bispecific...

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 - GTB-5550, which harbors wild-type IL-15, and BiKE display broad activity against B7-H3-expressing tumors ...

GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021 PR Newswire BEVERLY HILLS, Calif. , Nov. 30, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "C...

GT BioPharma to Host a Management Update Conference Call - Tuesday, November 30th at 4:30PM Eastern Time PR Newswire BEVERLY HILLS, Calif. , Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology...

GT Biopharma is an early-stage oncology company with one clinical asset. GT Biopharma will likely shift focus to their 2nd generation therapies, which are still preclinical. Lack of meaningful positive catalysts in the next year reduces attractiveness of investment. For furt...

GT Biopharma (NASDAQ:GTBP): Q3 GAAP EPS of -$0.17 beats by $0.04. Cash and cash equivalents of $35.8M. Press Release For further details see: GT Biopharma EPS beats by $0.04

GT BioPharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update -- Previously updated positive safety data for the GTB-3550 Phase 1 trial in relapsed/refractory AML and MDS with first-in-human trials, providing proof-of-concept support -- GTB-3650, se...

Gainers: Pioneer Power Solutions (NASDAQ:PPSI) +88%. CBAK Energy Technology (NASDAQ:CBAT) +39%. Arbe (NASDAQ:ARBE) +33%. The Trade Desk (NASDAQ:TTD) +29%. Autolus (NASDAQ:AUTL) +25%. Gaucho Group (NASDAQ:VINO) +24%. Cronos (NASDAQ:CRON) +21%. Bit Brother (NASDAQ:BTB) +22%. Lightbridge (NASDAQ...